| Trial | Patients n | Stage | 5-year survival benefit, % | Hazard ratio (95% CI) | p-value |
| ALPI | 1209 | I–IIIA | 3 | 0.96 (0.81–1.13) | 0.589 |
| IALT | 1867 | I–IIIA | 4 | 0.91 (0.81–1.02) | 0.03 |
| BLT | 381 | I–IIIA | 2 | 1.02 (0.77–1.35) | 0.90 |
| BR10 | 482 | IB–II | 15 | 0.69 (0.52–0.91) | 0.04 |
| ANITA | 840 | IB–IIIA | 9 | 0.8 (0.66–0.96) | 0.017 |
| LACE | 4584 | I–IIIA | 5 | 0.89 (0.82–0.96) | 0.004 |
| IGR-MRC | 8147 | I–IIIA | 4 | -0.87 (0.81–0.93) | <0.0000001 |
Reproduced from [3] with permission from the publisher.